GET DAILY SIGNALSAkari Therapeutics (AKTX): Analyst Targets Point to Potential +250% Upside
Key Takeaways
- The central target of $26 is the arithmetic mean of three current, post-reverse-split analyst price targets — $19.50, $27, and $30 — which average $25.50, rounded to $26.
- At a recent price near $7.45, reaching $26 would require upside of roughly 250%, an extremely large move.
- The verified analyst range is wide: from a low of $19.50 (Alliance Global Partners) to a high of $30 (Maxim Group), with all three ratings at Buy or Strong Buy.
- The strongest support is AKTX's differentiated PH1 payload platform and plans to start a Phase 1 trial for lead candidate AKTX-101 around mid-2027.
- The biggest risks are no revenue, persistent losses, reliance on equity financing, Nasdaq listing-compliance concerns, and clinical-stage uncertainty.
- For more information on Akari Therapeutics' Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
Analyst Price Targets and Consensus View
Three current, post-split analyst targets were reviewed. Alliance Global Partners analyst Matthew Venezia raised his target to $19.50 (September 16, 2026) while keeping a Buy rating, using a sum-of-the-parts framework that values AKTX-101 at about $11 per share, AKTX-102 at $3.75, and the PH1 payload plus cash at $4.75. H.C. Wainwright analyst Sean Lee reiterated a Buy with a $27 target (October 1, 2026). Maxim Group's Jason McCarthy reiterated a $30 target (August 18, 2026), having upgraded the stock to Buy from Hold in July 2026. Together these average $25.50, rounded to a $26 central target, with a $19.50-to-$30 range. An earlier $40 initiation from Ladenburg Thalmann (January 2026) predates the March reverse split and was excluded as stale. Because all three ratings are bullish, there is no published Hold or Sell view to offset them — a notable concentration of optimism on a very high-risk name. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock closed near $7.45 on November 11, 2026, within a 52-week range of $3.02 to $29.32. Reaching $26 would mean a gain of roughly 250%, which qualifies as a very large move rather than a modest or even substantial one. The path would almost certainly depend on de-risking events: successful completion of IND-enabling toxicology work, a clean entry into first-in-human dosing for AKTX-101 around mid-2027, and favorable early safety or efficacy signals. AKTX is not expected to generate revenue for years, so any move toward the target would be driven by news flow, clinical milestones, and potential licensing or partnership agreements rather than earnings.
What Could Support a Move Toward the Target
The bull case centers on the PH1 payload's differentiated mechanism. Management argues PH1 both kills tumor cells directly and activates innate and adaptive immune responses, positioning it as a next-generation alternative to conventional ADC payloads. AKTX-101 targets Trop2, a validated cancer antigen, while AKTX-102 targets CEACAM5. The company has presented data at multiple ADC conferences, reported interest from large pharmaceutical companies in novel payload technologies, and recently appointed Vatnak Vat-Ho as chief business officer, bringing two decades of oncology deal-making experience. GMP (good manufacturing practice) manufacturing is underway with WuXi XDC, and successful partnering could provide non-dilutive capital and external validation.
What Could Prevent the Target From Being Reached
The risks are substantial. AKTX has roughly six employees, no revenue, and ongoing losses, leaving it dependent on repeated equity financings that dilute existing shareholders. The 1-for-40 reverse split completed on March 31, 2026 was itself aimed at maintaining Nasdaq's minimum bid price, underscoring listing-compliance pressure. Preclinical promise does not guarantee clinical success, and many oncology assets fail in early trials. The ADC field is crowded, with large competitors and established programs against Trop2 and CEACAM5. Any delay, safety signal, financing shortfall, or Nasdaq delisting notice could sharply reprice the stock away from a $26 target.
Technical Levels and Market Structure
The stock trades below its 50-day and 200-day moving averages, which sat near $9.08 and $8.94 respectively in recent data, reflecting a weak long-term trend. The 52-week high of $29.32, just above the $30 high-end analyst target, marks the key resistance zone on the upside, while the $3.02 52-week low defines the lower boundary. The psychological $10 level, near the prior moving-average cluster, is a nearer-term hurdle the stock would need to reclaim before a move toward the analyst range becomes technically credible.
Time Horizon and What Investors Should Monitor
The three analyst targets reflect a roughly 12-month research horizon, though no single definitive timeframe was published. The most important upcoming items are the next earnings report (estimated for late November 2026), updates on IND-enabling studies and the planned mid-2027 Phase 1 start for AKTX-101, any partnership or licensing announcements, financing activity, and Nasdaq compliance status. Because analyst revisions can move a micro-cap quickly, changes to any of the three published targets also merit close attention. From what I see, monitoring these catalysts closely makes sense given the binary nature of the story.
Exploring AI Tools for Monitoring
In my view, tools that provide automated signals can add efficiency when following volatile names like this. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like AKTX, where sentiment can shift rapidly on a single clinical headline, automated monitoring can help traders discover opportunities, track positions, and spot changing trends more efficiently than manual review alone. Consider using these signals as part of a broader research process.
Final Assessment
The $26 central target is the rounded average of three verified analyst price targets spanning $19.50 to $30, all of which sit far above the recent price near $7.45. Reaching that level would require a roughly 250% gain, a very large move that depends on AKTX executing its ADC development plan without major setbacks. The strongest support is the differentiated PH1 payload platform and the mid-2027 Phase 1 catalyst, while the principal obstacles are the absence of revenue, persistent cash burn and dilution risk, and the inherent uncertainty of early-stage oncology development. The wide target range and the uniform bullishness among only three analysts underscore how speculative the setup remains. Investors should watch the clinical timeline, financing activity, and any analyst revisions, while recognizing that no price target — including $26 — is a guarantee. I’m watching this closely as events unfold.
Using Tickeron for Research
One thing that stands out when analyzing micro-cap biotechs is how AI-driven platforms can streamline the review of technical patterns and peer comparisons. I have found Tickeron's AI Daily Buy/Sell Signals helpful in this regard, offering a personal way to stay on top of developments without constant manual checks. It integrates well into a disciplined process for names where timing around catalysts matters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AKTX sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for AKTX moved above the 200-day moving average on October 21, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AKTX's RSI Indicator exited the oversold zone, 34 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTX advanced for three days, in 154 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
AKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKTX as a result. In 94 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AKTX turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 46 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
AKTX moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AKTX crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AKTX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. AKTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.820) is normal, around the industry mean (3.498). AKTX has a moderately high P/E Ratio (95.710) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (1.890) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology
Advertisement